ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GDR Genedrive Plc

1.825
-0.025 (-1.35%)
28 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025 -1.35% 1.825 1.75 1.90 1.85 1.825 1.85 1,731,938 09:33:46
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0447 -0.41 2.1M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 1.85p. Over the last year, Genedrive shares have traded in a share price range of 1.65p to 23.50p.

Genedrive currently has 115,139,946 shares in issue. The market capitalisation of Genedrive is £2.10 million. Genedrive has a price to earnings ratio (PE ratio) of -0.41.

Genedrive Share Discussion Threads

Showing 21126 to 21147 of 25650 messages
Chat Pages: Latest  846  845  844  843  842  841  840  839  838  837  836  835  Older
DateSubjectAuthorDiscuss
05/5/2023
09:50
As long as Riverfirt are involved I am staying clear.Good luck on first contract sale news
billthebank
05/5/2023
09:45
Tipped somewhere? Looks like a mass of PI gamblers not II's (imo) So potential crash back and more of no upbeat rns's shortly
pugugly
05/5/2023
09:44
Do you actually know if they have sold something at last? I have some in the bottom drawer but sold main part of my holding when Riverfort apppeared
billthebank
05/5/2023
09:39
Not small buys taking this up. Looks like they're about to announce a big deal and im not saying anything more so dont ask. It's about time since we've all been patiently waiting since NICE.

Fallen from 45p arena. Good luck

wrecktangle
05/5/2023
09:35
Shorts to get burnt if they added at 20p :)
g2theary
05/5/2023
09:27
40p :D incoming ;)
g2theary
03/5/2023
10:32
Dead cat bounce time Buy in for 15%
kirk 6
03/5/2023
09:41
DCB it is then :D
g2theary
02/5/2023
22:00
Contract wins and higher share price would make raising easier. Just cannot see it rising for a bit until the reverse placing has run its course.

Budd has a knack of throwing out "golden ticket" RNS's so who knows

The issue is no guidance at all on financials from budd - just that sales will be higher. Saying its going to be higher than £20k is laughable. Could mean anything.

The market has no faith in Budd, who has failed to deliver any meaningful sales ever.

thecroots
02/5/2023
21:51
Ok fair point ... however the product is a unique one and works. Surly contract wins and share price increases could make a placing much easier?
g2theary
02/5/2023
21:49
The Company is in ongoing dialogue still with the FDA to ascertain the requirements, and consequently the funding estimate that would be required to conduct and manage the evidence generation and submission process.Could easily be misconstrued... FDA Costs and Consulting Service Fees. How Much Does a FDA 510k Approval Cost? The vast majority of our FDA 510K clients generally spend in the range of $20,000-$30,000 to have their product or device prepared and reviewed before the actual FDA 510k submission process.Based on the above it could mean how much they need to pay ?
g2theary
02/5/2023
21:45
I have no idea how they will raise. The reverse placing is generally the last roll of the dice - especially so when credit tightness is here for a while.
thecroots
02/5/2023
21:43
Lol.. Says it right here!! lol

As announced on 9 February 2023, NICE had preliminarily recommended that the Genedrive(R) AIHL test can be used by the NHS following the evidence review as part of their Early Value Assessment (EVA) Programme . NICE concluded that the Genedrive(R)MT-RNR1 ID Kit can quickly and accurately identify babies with the primary genetic variant, there is currently no other test available in the NHS that provides results quickly enough to inform decisions on antibiotic prescribing in emergency care, the long-term savings to the NHS associated with hearing loss and fitting cochlear implants could be substantial. Final positive NICE guidance under their Early Value Assessment programme was issued on 30 March 2023 ratifying the 9 February decision . The Directors anticipate 6-8 UK Hospitals will be in various stages from "fully operational" to "approved and beginning implementation" within 3 months post NICE final publication and anticipate 6-8 non-UK distributors will be contracted by the end of the same timeframe. The US market represents a significant opportunity for the Group's AIHL test and an FDA "pre-submission" process is currently underway however additional funding would be required to progress the FDA approval process. The Company remains engaged with the FDA in the pre-submission process

thecroots
02/5/2023
20:40
Lol where Dow it say that lol
g2theary
02/5/2023
19:47
Lol - You'll need a raise to get an FDA licence. David Budd said that in the latest results!!!!!!
thecroots
02/5/2023
17:25
Anyway for me it's all about FDA approval here ... it's due to come within the next 6 weeks ;) DYOR Finance won't be in issue then.. share price potential multiples... I did say when I was trading these last back in balls deep covid ... they may as well use the £8M fund raise for the MT-RNR1 :) I'm only putting the profits that covid made me ... I was in here at 21p and sold out at 2.40p ;) I'll be selling out at over 100p this time ;) GLA
g2theary
02/5/2023
17:07
For continual draw downs? Correct?
g2theary
02/5/2023
16:08
PUT TOWER RESOURSES (TRP) ON YOUR WATCHLIST

AT A ALL TIME LOW

riskyinvestor
02/5/2023
15:28
They have already had the 1st 2M in early April ... correct?
g2theary
02/5/2023
15:11
Blimey, people don't understand a reverse placing.

32p was just the REFERENCE price, NOT the actual price. Adjustments are made as the share price falls. Meaning more shares have to be "created" meaning more dilution, meaning more a fall. A scenario that snowballs. Hence the term death sprial.

thecroots
02/5/2023
15:10
Share price says everything you need to know.
And it's not great is it.

angus17
02/5/2023
14:08
Thanks for so clearly demonstrating that you don't understand death spiral finance ;-).
terminator101
Chat Pages: Latest  846  845  844  843  842  841  840  839  838  837  836  835  Older